Pharmaceutical Research and Manufacturers of America — the drug industry's largest lobbying group — broke its silence on the controversy surrounding the high price of Marathon Pharmaceutical's newly approved muscular dystrophy drug, reports Endpoints News.
Marathon has faced much criticism this past week for setting the list price of Emflaza at $89,000. The generic treatment has been available on foreign markets for decades and only costs about $1,200 abroad.
PhRMA on Wednesday said Marathon is "guilty of conduct unbecoming to the industry" and shared plans to launch a review of the group's membership criteria, which could put Marathon CEO Jeff Aronin's seat on PhRMA's board in jeopardy, according to the report.
"We are pleased Marathon decided to pause the launch of their medicine to solicit additional input from patients and other stakeholders. Their recent actions are not consistent with the mission of our organization," PhRMA said in a statement Wednesday.
"In addition, the leadership of the PhRMA Board of Directors has begun a comprehensive review of our membership criteria to ensure we are focused on representing research-based biopharmaceutical companies who take significant risks to bring new treatments and cures to patients," the statement reads.
More articles on supply chain:
Integra to buy J&J's neurosurgery business for $1B
Winter storms exacerbate blood shortage in New England
Sen. Sanders to drugmaker: 'We're going to be your worst nightmare'